A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma

作者：Wang, Xian; Huang, Shan; Li, Xiaocan; Jiang, Dongrui; Yu, Hongzhen; Wu, Qiang; Gao, Chaobing^*; Wu, Zhengsheng^*

来源：PLos One, 2018, 13(7): e0200290.

DOI：10.1371/journal.pone.0200290

• BRAF V600E MUTATION
• HASHIMOTOS-THYROIDITIS
• CANCER
• EXPRESSION
• DIAGNOSIS
• SURVIVAL
• GROWTH
• GENE
• PROLIFERATION
• RECURRENCE

Papillary thyroid carcinoma (PTC) is the most common endocrine cancer with a significantly increase of the incidence recently. Several cytokines, such as thyroid peroxidase (TPO), cluster of differentiation 56 (CD56), Galectin-3, mesothelial cell (MC), cytokeratin 19 (CK19) and BRAF (B-raf) were recommended to be tested by immunohistochemistry (IHC) for a definitive diagnosis, but were still limited in clinical use because of their relative lower sensitivity and specificity. MicroRNA (miRNA), as a new molecular biomarkers, however, has not been reported yet so far. To address this, hsa-miR-200a-5p, a miRNA, was selected and detected in PTC patients by in situ hybrization with benign thyroid tumor with papillary hyperplasia as a control, and the differential expression of hsa-miR-200a-5p between fresh PTC tissues and control was detected by qRT-PCR. Expressive levels of cytokines of TPO, CD56, Galectin-3, MC, CK19 and B-raf were also detected by immunohistochemistry. The correlation was analyzed by SPSS software using Spearman methods. As expected, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, compared to that of control, and was consistent with that of TPO, CD56, Galectin-3, MC, CK19 and B-raf. In addition, expression of hsa-miR-200a-5p showed negative correlation to that of TPO (r(s) = - 0.734; **: P< 0.01) and CD56 (r(s) = - 0.570; **: P< 0.01), but positive correlation to that of Galectin-3 (r(s) = 0.601; **: P< 0.01), MC (r(s) = 0.508; **: P< 0.01), CK19 (r(s) = 0.712; **: P < 0.01) and B-raf (r(s) = 0.378; **: P < 0.01). PTC and papillary benign thyroid papillary hyperplasia are difficult to distinguish in morphology, so requiring immunohistochemistry to further differentiate the diagnosis, however, for the existing clinical common diagnostic marker for immunohistochemistry, the sensitivity and accuracy are low, it is easy to miss diagnosis. Therefore, there is an urgent need for a rapid and sensitive molecular marker. So miR-200a-5p can be used to assist in the diagnosis of PTC at the molecular level, and as a biomarker, can be effectively used to distinguish between PTC and benign thyroid tumor with papillary hyperplasia.

• 出版日期2018-7-13
• 单位安徽医科大学